Valion Bio, Inc. Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest
Valion Bio, Inc. (VBIO) reported Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest of -$7.06 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest · last filed 2026-08-14
- Valion Bio, Inc. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2026-06-30 was -$7.06M.
- Valion Bio, Inc. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2026-03-31 was -$6.22M.
- Valion Bio, Inc. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2026-03-30 was -$6.22M.
- Valion Bio, Inc. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2025-06-30 was -$1.68M.
- Valion Bio, Inc. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for fiscal 2025 was -$7.99M.
- Valion Bio, Inc. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for fiscal 2024 was -$4.47M.
| Period end | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 3 month | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 6 month | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 12 month |
|---|---|---|---|
| 2026-06-30 | -$7.06M 10-Q · filed 2026-08-14 | -$13.28M 10-Q · filed 2026-08-14 | |
| 2026-03-31 | -$6.22M 10-Q · filed 2026-05-14 | ||
| 2026-03-30 | -$6.22M 10-Q · filed 2026-05-14 | ||
| 2025-12-31 | -$7.99M 10-K · filed 2026-03-30 | ||
| 2025-06-30 | -$1.68M 10-Q · filed 2026-08-14 | -$3.05M 10-Q · filed 2026-08-14 | |
| 2025-03-31 | -$1.37M 10-Q · filed 2026-05-14 | ||
| 2024-12-31 | -$4.47M 10-K · filed 2026-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |